Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Oseltamivir Interaction of HEC116094 in Healthy Subjects
NCT04982913Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Aug 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC116094 in influenza (12 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Number of Adverse Events up to 26 days. Started Aug 2021; status: completed.
02
Drugs
HEC116094
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04982913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982913.